小细胞肺癌（SCLC）转化研究进展。
Advances in Small-Cell Lung Cancer (SCLC) Translational Research.
机构信息
University of Texas Southwestern Medical Center, Dallas, Texas 75390, USA.
Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA.
出版信息
Cold Spring Harb Perspect Med. 2021 Apr 1;11(4):a038240. doi: 10.1101/cshperspect.a038240.
Over the past several years, we have witnessed a resurgence of interest in the biology and therapeutic vulnerabilities of small-cell lung cancer (SCLC). This has been driven in part through the development of a more extensive array of representative models of disease, including a diverse variety of genetically engineered mouse models and human tumor xenografts. Herein, we review recent progress in SCLC model development, and consider some of the particularly active avenues of translational research in SCLC, including interrogation of intratumoral heterogeneity, insights into the cell of origin and oncogenic drivers, mechanisms of chemoresistance, and new therapeutic opportunities including biomarker-directed targeted therapies and immunotherapies. Whereas SCLC remains a highly lethal disease, these new avenues of translational research, bringing together mechanism-based preclinical and clinical research, offer new hope for patients with SCLC.
在过去的几年中，我们见证了人们对小细胞肺癌（SCLC）生物学和治疗弱点的兴趣再次兴起。这部分是通过开发更广泛的疾病代表性模型阵列驱动的，包括各种基因工程小鼠模型和人肿瘤异种移植物。在此，我们回顾了 SCLC 模型开发的最新进展，并考虑了 SCLC 中一些特别活跃的转化研究途径，包括肿瘤内异质性的研究、对起源细胞和致癌驱动因素的深入了解、化疗耐药机制，以及新的治疗机会，包括基于生物标志物的靶向治疗和免疫治疗。尽管 SCLC 仍然是一种高度致命的疾病，但这些新的转化研究途径将基于机制的临床前和临床研究结合在一起，为 SCLC 患者带来了新的希望。
Zotero 插件